Why the study?
Does low-dose amiloride have noninferiority to spironolactone in patients with resistant hypertension?
Does low-dose amiloride have noninferiority to spironolactone in patients with resistant hypertension?
Highlights additional considerations for therapeutic selection and trial design when comparing amiloride and spironolactone for resistant hypertension.
To the Editor In an Editorial, Dr Brook and colleagues summarize low-dose amiloride’s noninferiority to spironolactone for resistant hypertension, yet several additional considerations warrant emphasis to refine therapeutic selection and trial design.1
No takes yet. Share an insight, caveat, or question.
Xu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: